Glioblastoma del adultoFase 1NCT04573140Artículos
ARNm tumoral total autólogo
Vacunas de partículas lipídicas de ARN (ARN-LP) para gliomas pediátricos de alto grado (GAGp) y glioblastoma (GBM) del adulto recién diagnosticados
HSV G207 en niños con tumores cerebrales cerebelosos recurrentes o refractarios
Lo que dice el vídeo
Most childhood brain tumors start in the cerebellum, low at the back of the head, where balance and coordination live. That is where medulloblastoma begins, the most common malignant brain tumor of childhood.
Treatment is a hard road: surgery, radiation to the whole brain and spine, then months of chemotherapy. Many children are cured, but it is tough on a growing brain. And when the tumor comes back after all of that, there are very few options left. That is the problem this trial is trying to solve.
Here is the idea. What if the treatment were a virus?
Almost everyone has met herpes simplex virus type one, the cold-sore virus. It is naturally good at getting into nerve cells. Scientists rebuilt it so it can grow inside cancer cells, but not healthy brain. The rebuilt virus is called G207. The strategy: let it do what viruses do, only inside the tumor, and let the immune system notice.
How does it work? Two edits to the virus's genes.
The first edit takes away the virus's key. Every healthy cell has an alarm: when it senses a virus, an enzyme called PKR shuts down the cell's protein factory, and the infection stalls. Natural herpes carries a gene that switches that alarm off. Scientists deleted it. Now healthy cells stop G207. But many cancer cells disabled that alarm on their way to becoming cancer. Inside them, G207 multiplies.
The second edit takes away a tool. To copy itself, the virus needs an enzyme that builds DNA. Scientists broke the virus's own copy, so G207 must borrow it from the cell it is in, and only dividing cells have it. Tumor cells divide constantly. Most mature brain cells do not.
Together, the two edits mean the virus can only thrive in the tumor. It multiplies inside cancer cells until they burst, spreads to the cancer cells next door, and all that debris draws in the immune system.
That last part may matter most. In the first trial of G207 in children, biopsies before treatment showed almost no immune cells in the tumor, what doctors call a cold tumor. Months later, the same tumors were crowded with T cells. Twelve children were treated. No serious side effects were blamed on the virus, and median survival was twelve point two months, against a historical five point six. A small first study, not proof, published in the New England Journal of Medicine in twenty twenty-one.
One more piece. In the lab, a small dose of radiation makes tumor cells produce more of the very enzyme the virus lost, which helps it multiply. So most children in this trial get one low dose of radiation the day after the virus.
That first trial treated the upper brain. This one takes G207 to the cerebellum for the first time, after mouse studies showed it was safe there. Children and young adults from three to twenty-one whose cerebellar tumor has returned receive a single infusion of G207 through fine catheters placed in the tumor. The first question is safety; the second is dose. It is led by Gregory Friedman at M D Anderson, with sites in Houston, Birmingham, and St. Louis.
Everything in this film comes from the published record, and it is not medical advice.
Fuentes de este vídeo
Bernstock JD. Cancer Gene Ther, 2020
Most childhood brain tumors start in the cerebellum; it handles balance and coordination; Medulloblastoma is the most common malignant brain tumor of childhood; Treatment is surgery, radiation to whole brain and spine (craniospinal), months of chemotherapy; tough on a growing brain; few options at recurrence; "Many children are cured" (+3 more lines)
Bernstock JD. Hum Gene Ther, 2020
Treatment is surgery, radiation to whole brain and spine (craniospinal), months of chemotherapy; tough on a growing brain; few options at recurrence; Standard treatment is "harmful to the developing brain"; This trial: ages 3–21, recurrent/progressive cerebellar tumors, single infusion via intratumoral catheters, 3+3 design, four cohorts, first cohort virus alone, cohorts 2–4 add 5 Gy within 24 h, primary goal safety
Treatment is surgery, radiation to whole brain and spine (craniospinal), months of chemotherapy; tough on a growing brain; few options at recurrence; Two edits: "takes away the key" (γ34.5 deletion) and "takes away a tool" (ICP6/ribonucleotide reductase); HSV-1 is the cold-sore virus and naturally infects nerve cells; G207 is HSV-1 (strain F) engineered to replicate in tumor cells, not normal brain (+4 more lines)
Friedman GK. N Engl J Med, 2021
Twelve children treated (ages 7–18, recurrent/progressive high-grade glioma); First pediatric trial: 12 children, recurrent/progressive high-grade glioma, ages 7–18; no DLT or SAE attributed to G207; median OS 12.2 mo vs historical 5.6 mo; pre-treatment biopsies "cold", post-treatment tumors with many T cells; NEJM April 2021; That trial was supratentorial
G207 is HSV-1 (strain F) engineered to replicate in tumor cells, not normal brain; Edit 2: UL39/ICP6 (viral ribonucleotide reductase) inactivated by lacZ insertion; needed for viral DNA synthesis in non-dividing cells; dividing cells supply the cellular equivalent
Todo T. Front Biosci, 2008
Edit 1: both copies of γ34.5 deleted; γ34.5 counters the PKR shutdown of protein synthesis; tumor cells have low PKR activity so the deleted virus still replicates there
Wilcox DR. PLoS Pathog, 2016
Edit 1: both copies of γ34.5 deleted; γ34.5 counters the PKR shutdown of protein synthesis; tumor cells have low PKR activity so the deleted virus still replicates there
Kangas C. Viruses, 2021
"Many" not "all" cancer cells have low PKR — heterogeneity
Scanlan H. Front Oncol, 2022
Edit 2: UL39/ICP6 (viral ribonucleotide reductase) inactivated by lacZ insertion; needed for viral DNA synthesis in non-dividing cells; dividing cells supply the cellular equivalent
Markert JM. Mol Ther, 2014
Low-dose radiation upregulates cellular ribonucleotide reductase, the enzyme G207 lacks, enhancing replication
Stanziale SF. Surgery, 2002
Low-dose radiation upregulates cellular ribonucleotide reductase, the enzyme G207 lacks, enhancing replication
El fármaco
Dosis única de G207 infundida mediante catéteres en la(s) región(es) del tumor. Si G207 resulta seguro en la primera cohorte, los siguientes pacientes recibirán una dosis única de G207 mediante catéteres en la(s) región(es) del tumor, seguida de una dosis de radiación de 5 Gy sobre el tumor (incluida la enfermedad leptomeníngea progresiva o cualquier foco de tumor macroscópico en progresión en el parénquima cerebral) en las 24 horas siguientes a la inoculación del virus.
El pronóstico de los niños con tumores cerebrales malignos cerebelosos recurrentes o progresivos es muy malo, y faltan tratamientos de rescate eficaces cuando fracasan los tratamientos estándar. G207 es un virus del herpes simple tipo 1 (HSV) oncolítico al que se han introducido con éxito mutaciones que le permiten replicarse selectivamente en las células cancerosas y destruirlas, pero no en las células normales.
La replicación de G207 en el tumor no solo destruye las células tumorales infectadas, sino que convierte a la célula tumoral en una fábrica de virus nuevos. Estas partículas virales se liberan cuando la célula tumoral muere y pueden infectar a otras células tumorales cercanas, continuando el proceso de destrucción del tumor.
El estudio
Este estudio es un ensayo clínico para determinar la seguridad de inocular G207 (una terapia experimental con virus) en un tumor cerebral cerebeloso recurrente o refractario. También se evaluará la seguridad de combinar G207 con una única dosis baja de radiación, diseñada para potenciar la replicación del virus, la destrucción de las células tumorales y una respuesta inmunitaria antitumoral. Fuente de financiación: FDA OOPD
Requisitos
Criterios de inclusión tal como figuran en el registro, recortados. La lista completa, con las exclusiones, está en el registro actualizado.
Para ti, o para alguien a quien quieres
Un diagnóstico complejo trae preguntas nuevas cada semana, dentro de un ensayo y fuera de él. Triangle reúne todo tu expediente médico, lo lee contigo en lenguaje claro y te ayuda, a ti y a tu familia, a decidir qué preguntar después.
Después, $9 al mes. Cancela cuando quieras.
Solicitados a tus hospitales y clínicas a través de las redes nacionales. Añade estudios de imagen, patología y cualquier documento en papel.
Informes explicados a medida que llegan, con valores de laboratorio que puedes seguir antes del tratamiento, durante un ensayo y después.
Pregunta sobre tu propio expediente y llega con preguntas para tu oncólogo o el equipo del ensayo.
Comparte un mismo perfil con la familia que te ayuda y con tus médicos.
Los miembros también reciben un análisis profundo de sus historiales y de cualquier dato de secuenciación, incluidos los ensayos clínicos que podrían encajar, revisado por un médico colegiado antes de recibirlo.
Se convierte en un proyecto que hay que manejar: citas, estudios de imagen, análisis, efectos secundarios y papeleo. Triangle lo mantiene organizado en un solo lugar, para ti o para quien te ayuda.
Organizar mi ensayoPrueba gratuita de 7 días, después $9 al mes. Cancela cuando quieras.
Cómo funcionan estos ensayos: qué es de verdad la fase 1 · preguntas frecuentes No es evidencia clínica.